Proteus Digital Health, the ingestible sensor company that raised $45 million in May -- the largest funding raise in digital health this year so far -- has published the results of a small clinical trial in a peer-reviewed journal. The study of 27 adults with bipolar disorder or schizophrenia found that the addition of an ingestible sensor to their regiment led to 67 percent of patients taking...